Loading patent…
AssigneeUniversity of Connecticut Health Center
InventorsPramod Srivastava, Zihai Li
Estimating the term…
The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or α2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
A method of treating cancer in a subject comprising:
A method of treating chronic myelogenous leukemia in a subject comprising:
A method of treating CML in a subject receiving 200 mg to 800 mg of imatinib mesylate daily comprising administering a heat shock protein preparation to said subject, wherein said heat shock protein preparation comprises hsp70-peptide complexes.
A kit comprising a first container containing a purified heat shock protein preparation and a second container containing imatinib mesylate.
A pharmaceutical composition comprising a purified heat shock protein preparation and imatinib mesylate.
Dependencies are inferred from the claim text.